The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
Abstract
Purpose: Germline mutations in DNA damage repair (DDR) genes are identified in a significant proportion of patients with metastatic prostate cancer, but the clinical implications of these genes remain unclear. This prospective multicenter cohort study evaluated the prevalence and effect of germline DDR (gDDR) mutations on metastatic castration-resistance prostate cancer (mCRPC) outcomes. Patients and Methods: Unselected patients were enrolled at diagnosis of mCRPC and were screened for gDDR mutations in 107 genes. The primary aim was to assess the impact of ATM/BRCA1/BRCA2/ PALB2 germline mutations on cause-specific survival (CSS) from diagnosis of mCRPC. Secondary aims included the association of gDDR subgroups with response outcomes for mCRPC treatments. Combined progression-free survival from the first systemic therapy (PFS) until progression on the second systemic therapy (PFS2) was also explored. Results: We identified 68 carriers (16.2%) of 419 eligible patients, including 14 with BRCA2, eight with ATM, four with BRCA1, and none with PALB2 mutations. The study did not reach its primary end point, because the difference in CSS between ATM/BRCA1/BRCA2/PALB2 carriers and noncarriers was not statistically significant (23.3 v 33.2 months; P = .264). CSS was halved in germline BRCA2 (g BRCA2) carriers (17.4 v 33.2 months; P = .027), and g BRCA2 mutations were identified as an independent prognostic factor for CCS (hazard ratio [HR], 2.11; P = .033). Significant interactions between g BRCA2 status and treatment type (androgen signaling inhibitor v taxane therapy) were observed (CSS adjusted P = .014; PFS2 adjusted P = .005). CSS (24.0 v 17.0 months) and PFS2 (18.9 v 8.6 months) were greater in g BRCA2 carriers treated in first line with abiraterone or enzalutamide compared with taxanes. Clinical outcomes did not differ by treatment type in noncarriers. Conclusion: g BRCA2 mutations have a deleterious impact on mCRPC outcomes that may be affected by the first line of treatment used. Determination of g BRCA2 status may be of assistance for the selection of the initial treatment in mCRPC. Nonetheless, confirmatory studies are required before these results can support a change in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationCastro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.053 · Cited by 571
Self-citationAnnala, M., Vandekerkhove, G., Khalaf, D., Taavitsainen, S., Beja, K., Warner, E. W., Sunderland, K., Kollmannsberger, C., Eigl, B. J., Finch, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0937 · Cited by 515
Mandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.11137 · Cited by 511
A recurrent mutation in PALB2 in Finnish cancer families
Erkko, H., Xia, B., Nikkilä, J., Schleutker, J., Syrjäkoski, K., Mannermaa, A., Kallioniemi, A., Pylkäs, K., Karppinen, S.-M., Rapakko, K., et al. (2007) · Nature · doi:10.1038/nature05609 · Cited by 466
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0261 · Cited by 421
Collaborators, T. U., Kote-Jarai, Z., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Castro, E., Mahmud, N., Guy, M., Edwards, S., O'Brien, L., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.383 · Cited by 399
Self-citationCastro, E., Goh, C., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Dadaev, T., Govindasami, K., Guy, M., Ellis, S., Frost, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.022 · Cited by 368
Self-citationGermline BRCA1 mutations increase prostate cancer risk
Collaborators, T. U., Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., Goh, C., Govindasami, K., Guy, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.146 · Cited by 302
Self-citationQuigley, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0146 · Cited by 273
Self-citationRubinstein, L. V., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 267
Cheng, H. H., Pritchard, C. C., Boyd, T., Nelson, P. S., & Montgomery, B. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.022 · Cited by 261
Self-citationThe genetic epidemiology of prostate cancer and its clinical implications
Eeles, R., Goh, C., Castro, E., Bancroft, E., Guy, M., Olama, A. A. A., Easton, D., & Kote-Jarai, Z. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2013.266 · Cited by 260
Self-citationPomerantz, M. M., Spisák, S., Jia, L., Cronin, A. M., Csabai, I., Ledet, E., Sartor, A. O., Rainville, I., O'Connor, E. P., Herbert, Z. T., et al. (2017) · Cancer · doi:10.1002/cncr.30808 · Cited by 257
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
Taylor, R. A., Fraser, M., Livingstone, J., Espiritu, S. M. G., Thorne, H., Huang, V., Lo, W., Shiah, Y.-J., Yamaguchi, T. N., Sliwinski, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms13671 · Cited by 234
Janavičius, R. (2010) · EPMA Journal · doi:10.1007/s13167-010-0037-y · Cited by 223
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
Annala, M., Struss, W. J., Warner, E. W., Beja, K., Vandekerkhove, G., Wong, A., Khalaf, D., Seppälä, I.-L., So, A., Lo, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.023 · Cited by 218
Hussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y.-M., Robinson, D., Lonigro, R. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7310 · Cited by 206
Antonarakis, E. S., Lu, C., Luber, B., Liang, C., Wang, H., Chen, Y., Silberstein, J. L., Piana, D., Lai, Z., Chen, Y., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.035 · Cited by 179
Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH
Win, A. K., Reece, J. C., Dowty, J. G., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30197 · Cited by 157
Velho, P. I., Silberstein, J. L., Markowski, M. C., Luo, J., Lotan, T. L., Isaacs, W. B., & Antonarakis, E. S. (2018) · The Prostate · doi:10.1002/pros.23484 · Cited by 141
Mateo, J., Cheng, H. H., Beltran, H., Dolling, D. I., Xu, W., Pritchard, C. C., Mossop, H., Rescigno, P., Pérez-López, R., Sailer, V., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.010 · Cited by 127
Self-citationOsório, A., Rodríguez‐López, R., Dı́ez, O., de la Hoya, M., Martínez, J. I., Vega, A. I., Esteban‐Cardeñosa, E., Alonso, C., Caldés, T., & Benitez, J. J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11414 · Cited by 81
Risk of Cancer byATMMissense Mutations in the General Population
Dombernowsky, S. L., Weischer, M., Allin, K. H., Bojesen, S. E., Tybjjrg-Hansen, A., & Nordestgaard, B. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6613 · Cited by 71
Castro, E., Jugurnauth-Little, S., Karlsson, Q., Al‐Shahrour, F., Piñeiro-Yáñez, E., de Poll, F. V., Leongamornlert, D. A., Dadaev, T., Govindasami, K., Guy, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv356 · Cited by 44
Self-citationMutations in BRCA2 and taxane resistance in prostate cancer
Nientiedt, C., Heller, M., Endris, V., Volckmar, A., Zschäbitz, S., Tapia-Laliena, M. Á., Duensing, A. U., Jäger, D., Schirmacher, P., Sültmann, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04897-x · Cited by 43
González‐Rivera, M., Lobo, M., López‐Tarruella, S., Jerez, Y., del Monte-Millán, M., Massarrah, T., Ramos‐Medina, R., Ocaña, I., Picornell, A. C., Garzón, S. S., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3792-1 · Cited by 39
Tavera-Tapia, A., Pérez‐Cabornero, L., Macías, J. A., Ceballos, M. I., Roncador, G., de la Hoya, M., Barroso, A., Felipe-Ponce, V., Serrano‐Blanch, R., Hinojo, C., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4058-7 · Cited by 21
Cited by
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationProstate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Self-citationProstate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 596
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01649 · Cited by 355
“9 months in the BRCA1/2 subgroup that received AAP alone compared with the historical rPFS of approximately 16 months in unselected patients.(6,27-29) These findings are consistent with prior reports of patients with BRCA1/2 gene alterations having poor prognosis and worse treatment outcomes with standard therapies.”
ResultSelf-citation
Metadata
- Authors
- Castro, E., Romero-Laorden, N., del Pozo, A., Lozano, R., Medina, A., Puente, J., Piulats, J. M., Lorente, D., Saez, M. I., Morales-Barrera, R., Gonzalez-Billalabeitia, E., Cendón, Y., García-Carbonero, I., Borrega, P., Mendez Vidal, M. J., Montesa, A., Nombela, P., Fernández-Parra, E., Gonzalez del Alba, A., Villa-Guzmán, J. C., Ibáñez, K., Rodriguez-Vida, A., Magraner-Pardo, L., Perez-Valderrama, B., Vallespín, E., Gallardo, E., Vazquez, S., Pritchard, C. C., Lapunzina, P., & Olmos, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-02-20
- Volume
- 37
- Issue
- 6
- Pages
- 490-503
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2908857416
- Cited by
- 377
- References
- 35
- FWCI
- 32.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.